| Data indicate that all deltaWT tumors had activating mutations in KRAS, whereas only 69% of deltaKO tumors did, suggesting that PKCdelta acts as a tumor promoter downstream of oncogenic K-ras while acting as a tumor suppressor in other oncogenic contexts. | None |
| Rac1 is essential for K-Ras driven epithelial cell hyperproliferation and that Rac1 activity is elevated in tissues expressing mutant oncogenic K-Ras. | None |
| Impact of oncogenic K-RAS on YB-1 phosphorylation induced by ionizing radiation. | None |
| Syndecan-1 and -4 differentially regulate oncogenic K-ras dependent cell invasion | None |
| Accumulation of p21ras.GTP in response to stimulation with epidermal growth factor and oncogene products with tyrosine kinase activity. | None |
| p21Waf1 is required for complete oncogenic transformation of mouse embryo fibroblasts by E1Aad5 and c-Ha-ras oncogenes. | None |
| Genotype markers and proto-oncogene analysis in the CD30-positive malignant histiocytosis DEL cell line with t(5;6)(q35;p21). | None |
| Inhibition of miR-193a expression by Max and RXRalpha activates K-Ras and PLAU to mediate distinct aspects of cellular transformation. | None |
| Rb encodes a tumor suppressor that attenuates progression of oncogenic Kras-induced carcinogenesis in the pancreas by mediating the senescence response and promoting activity of the tumor suppressor p53. | None |
| mitochondrial functional loss may be mediated by oncogenic K-Ras-induced mitophagy during early tumorigenesis even in the absence of hypoxia | None |
| Under serum-starved conditions, the expression level of RRM2 protein increased in HCT116 cells compared to HKe3 cells (HCT116 cells with a disruption in oncogenic KRAS), and the re-expression of KRAS in HKe3 cells induced the expression of RRM2. | None |
| Kinetic evidence of a rapid activation of phosphatidylcholine hydrolysis by Ki-ras oncogene. Possible involvement in late steps of the mitogenic cascade. | None |
| K-ras oncogene expression in Xenopus laevis. | None |
| ras-induced down-regulation of caspase-2 represents a novel mechanism by which oncogenic Ras protects malignant intestinal epithelial cells from anoikis | None |
| Ki-ras oncogene mutations in non-HPV-associated anal carcinoma. | None |
| Photoactivated cationic alkyl-substituted porphyrin binding to g4-RNA in the 5 -UTR of KRAS oncogene represses translation. | None |
| This is the first description of an oncogenic gene fusion of KRAS, one of the most studied proto-oncogenes. | None |
| Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. | None |
| Report of oncogenic BRAF/KRAS mutations in sporadic glomus tumors. | None |
| Detection of point mutations in KRAS oncogene by real-time PCR-based genotyping assay in GIT diseases. | None |